Related Experiment Video
Updated: Nov 12, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Impact of a Thoracic Multidisciplinary Conference on Lung Cancer Outcomes.
Carmelo Gaudioso1, Alexis Sykes2, Philip E Whalen1
1Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Multidisciplinary conferences (MDCs) significantly improved lung cancer survival and adherence to National Comprehensive Cancer Network (NCCN) guidelines. Patients with advanced lung cancer stages III/IV experienced the greatest survival benefit from MDC discussions.
Area of Science:
- Oncology
- Clinical Research
- Public Health
Background:
- Multidisciplinary conferences (MDCs) are increasingly vital for complex cancer treatment decisions.
- Evaluating the impact of a thoracic MDC (T-MDC) on lung cancer care quality and survival is critical.
Purpose of the Study:
- To assess the impact of a thoracic multidisciplinary conference (T-MDC) on lung cancer patient survival.
- To evaluate the effect of T-MDC on adherence to National Comprehensive Cancer Network (NCCN) guidelines.
Main Methods:
- A retrospective study comparing 300 lung cancer patients discussed at T-MDC with 300 matched controls.
- Survival analysis using Kaplan-Meier methods and NCCN guideline compliance assessment.
Main Results:
- T-MDC discussion led to improved median overall survival (36.9 vs 19.3 months) and cancer-specific survival (48 vs 28.1 months).
- Significant survival benefits were observed in advanced stage (III/IV) lung cancer patients.
- NCCN guideline compliance increased from 80% to 94% post-T-MDC discussion, with 41% of treatment plans altered.
Conclusions:
- Lung cancer patients benefit from T-MDC discussion, particularly those with advanced disease.
- T-MDC enhances the quality of lung cancer care and improves survival outcomes.
- Further research is needed to elucidate the mechanisms behind these survival benefits.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
COPD: Management Using Bronchodilators and Corticosteroids
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation

